Skip to main content

News Release

 
Printer Friendly Version View printer-friendly version
<< Back
HeartWare to Report Financial Results for Second Quarter of 2011

FRAMINGHAM, Mass. and SYDNEY, July 27, 2011 /PRNewswire via COMTEX/ --

HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) plans to release financial results for the second quarter and six months ended June 30, 2011, after the close of the U.S. stock markets on Thursday, August 4, 2011.

A conference call with management is scheduled for 5:00 pm U.S. Eastern Daylight Time on Thursday, August 4, 2011 (being 7:00 am Australian Eastern Standard Time, Friday, August 5, 2011) to discuss the Company's financial results, highlights from the quarter and business outlook. The call may be accessed by dialing 1-877-941-4775 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial + 1-480-629-9761.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Second Quarter 2011 Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's web site, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy. For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.